CD4+/CD56+ hematodermic neoplasm

This trial tests a new type of cell therapy for people with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has come back or not responded to standard treatment. The therapy uses a patient's own natural killer (NK) cells, engineered to re…

This study tests a new treatment plan for people with a rare and aggressive blood cancer called BPDCN. The plan combines two targeted drugs (tagraxofusp and venetoclax) with standard chemotherapy to kill cancer cells. The goal is to see if this combination can control the disease…

This study tests a standardized, optimized approach to cord blood transplantation for adults with high-risk blood cancers like leukemia and lymphoma. The method includes specific chemotherapy, radiation, and stem cell dosing, followed by careful monitoring. Researchers hope to im…

This registry study is following adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer, who are being treated with the drug tagraxofusp (ELZONRIS) in routine clinical care. The goal is to see how effective the treatment is at achievi…

This study tests a special cord blood transplant for people with high-risk blood cancers like leukemia and lymphoma. Participants get chemotherapy and radiation before the transplant to kill cancer cells and prepare the body. After the transplant, drugs are given to prevent the n…

This study tests a two-drug combination (tagraxofusp and venetoclax) in adults with a rare and aggressive blood cancer called BPDCN who have not had prior treatment. The main goal is to see if the combination can achieve complete remission after 3 months. Depending on results, pa…

This early-phase study tests a new drug called SL-401 combined with two other drugs (azacitidine and venetoclax) in people with certain blood cancers—acute myeloid leukemia, myelodysplastic syndrome, and blastic plasmacytoid dendritic cell neoplasm. The main goal is to find the s…

This early-phase trial tests a new treatment called CD123-CAR T cells for children and young adults (up to age 21) with certain types of leukemia or related blood cancers that have come back or not responded to standard therapy. The treatment involves collecting the patient's own…

This early-phase trial tests a new immunotherapy for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered donor T cells designed to recognize and attack a protein called HA-1 found …

This study tests a new drug called lisaftoclax, alone or combined with other medicines, in people with acute myeloid leukemia that has come back or not responded to treatment. The main goals are to check safety and find the best dose. About 682 adults will take part across multip…

This study looks back at the medical records of about 140 people with a rare blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN) who received chemotherapy as their first treatment. The goal is to see how effective and safe different chemotherapy regimens are …

This study creates a worldwide registry for people diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a very rare blood cancer. Researchers will collect information on how the disease presents, how it is treated, and what happens to patients over time. The goal …